Rapid Onset of Clinical Response to Eculizumab in a Single-Center Cohort of Older Patients with Refractory Generalized Myasthenia Gravis
Giulia D’Alvano, Salvatore Del Giudice, Francesca D’Anna, Vincenzo Todisco, Alessandro Tessitore, Alvino Bisecco · 2026
Read Rapid Onset of Clinical Response to Eculizumab in a Single-Center Cohort of Older Patients with Refractory Generalized Myasthenia Gravis by Giulia D’Alvano, Salvatore Del Giudice, Francesca D’Anna, Vincenzo Todisco, Alessandro Tessitore, Alvino Bisecco (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13516849.txt.
Description
Giulia D'Alvano and five colleagues report how fast a targeted antibody works in hard-to-treat myasthenia gravis, in a 2026 single-centre study. The drug, eculizumab, blocks a complement protein and is approved for patients whose disease defies standard therapy and who carry a certain antibody type. Eight older patients, averaging seventy-three years, were scored for daily function and muscle strength before treatment, at five weeks, and at three months.
Improvement came quickly. Daily-living scores fell by roughly three-quarters within five weeks, and strength scores fell by about three-fifths, both shifts being large and statistically firm. Gains held at three months. The drug was well tolerated in this small group. D'Alvano's team reads the speed as clinically valuable for frail, elderly patients who need early relief. Eight patients at one centre still make a narrow evidence base.
Catalog record
| CREATOR | Giulia D’Alvano, Salvatore Del Giudice, Francesca D’Anna, Vincenzo Todisco, Alessandro Tessitore, Alvino Bisecco |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |